Log EC50 | Log EC50 in presence of PTX | Emax (response without PTX) | n | |
---|---|---|---|---|
% | ||||
cAMP Accumulation Agonists | ||||
Labetolol | −8.04 ± 0.06 | −7.93 ± 0.16 | 94.1 ± 3.9 | 3 |
Alprenolol | −9.07 ± 0.09 | −9.05 ± 0.18 | 96.4 ± 5.3 | 3 |
Inverse agonists ICI 118551 | −8.85 ± 0.08 | −8.91 ± 0.06 | 98.8 ± 1.8 | 5 |
Propranolol (±)-Propranolol | −9.14 ± 0.10 | −9.00 ± 0.14 | 95.1 ± 2.2 | 4 |
CRE-SPAP Production Agonists | ||||
Isoprenaline | −8.20 ± 0.16 | −8.33 ± 0.18 | 99.0 ± 4.4 | 9 |
Salbutamol | −8.62 ± 0.04 | −8.63 ± 0.12 | 102.5 ± 3.6 | 6 |
Salmeterol | −10.52 ± 0.08 | −10.57 ± 0.08 | 99.0 ± 4.8 | 3 |
CGP 12177 | −9.53 ± 0.05 | −9.70 ± 0.06 | 102.0 ± 5.7 | 3 |
Labetolol | −8.82 ± 0.05 | −8.72 ± 0.05 | 101.1 ± 0.8 | 3 |
Acebutolol | −6.39 ± 0.09 | −6.38 ± 0.06 | 108.2 ± 8.6 | 3 |
Pindolol | −9.25 ± 0.02 | −9.31 ± 0.02 | 101.4 ± 5.9 | 3 |
Alprenolol | −9.49 ± 0.03 | −9.56 ± 0.14 | 109.0 ± 2.8 | 3 |
Inverse agonists ICI 118551a | −9.52 ± 0.047 | −9.47 ± 0.08 | 109.2 ± 8.2 | 3 |
Propranolol (±)-Propranolol | −9.58 ± 0.12 | −9.35 ± 0.08 | 118.4 ± 15.1 | 4 |
↵ a To maximize the chance of seeing any change to this small inverse agonist response, 100 nM forskolin was added to all wells (both those with and without PTX incubation) to increase the `basal' adenylyl cyclase activity. Under these conditions, in the absence of PTX, ICI 118551 reduced basal to 54.9 ± 2.0% of untreated (n = 3).